James Palacino

Company: Orum Therapeutics

Job title: Vice President & Head of Biology

Seminars:

Development of TPD² – Combining the Power of Protein Degradation With the Precision of Antibodies for Next-Generation ADCs 8:30 am

Examining the potency of GSPT1 degrader as a payload Discussing improved pharmacokinetic properties Outlining improved safety and tolerabilityRead more

day: Scientific Program Day Two